Cargando…
“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
BACKGROUND: The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising outcomes, there were limited apheresis/production slots for ide-cel. We report outcomes of...
Autores principales: | Ahmed, Nausheen, Wesson, William, Mushtaq, Muhammad Umair, Bansal, Rajat, AbdelHakim, Haitham, Bromert, Sarah, Appenfeller, Allison, Ghazal, Batool Abu, Singh, Anurag, Abhyankar, Sunil, Ganguly, Siddhartha, McGuirk, Joseph, Abdallah, Al-Ola, Shune, Leyla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436079/ https://www.ncbi.nlm.nih.gov/pubmed/37601685 http://dx.doi.org/10.3389/fonc.2023.1206715 |
Ejemplares similares
-
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients
por: Mushtaq, Muhammad Umair, et al.
Publicado: (2021) -
Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
por: Mushtaq, Muhammad Umair, et al.
Publicado: (2022) -
Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
por: Mushtaq, Muhammad Umair, et al.
Publicado: (2023) -
Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021) -
Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)